JP2014034577A5 - - Google Patents

Download PDF

Info

Publication number
JP2014034577A5
JP2014034577A5 JP2013226693A JP2013226693A JP2014034577A5 JP 2014034577 A5 JP2014034577 A5 JP 2014034577A5 JP 2013226693 A JP2013226693 A JP 2013226693A JP 2013226693 A JP2013226693 A JP 2013226693A JP 2014034577 A5 JP2014034577 A5 JP 2014034577A5
Authority
JP
Japan
Prior art keywords
csf
mgd
shows
cells
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013226693A
Other languages
English (en)
Japanese (ja)
Other versions
JP5815638B2 (ja
JP2014034577A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014034577A publication Critical patent/JP2014034577A/ja
Publication of JP2014034577A5 publication Critical patent/JP2014034577A5/ja
Application granted granted Critical
Publication of JP5815638B2 publication Critical patent/JP5815638B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2013226693A 2004-07-22 2013-10-31 疾患処置におけるｍｇｄ−ｃｓｆのための組成物およびその使用方法 Expired - Fee Related JP5815638B2 (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US59056504P 2004-07-22 2004-07-22
US60/590,565 2004-07-22
US64760405P 2005-01-27 2005-01-27
US60/647,604 2005-01-27
US66493205P 2005-03-24 2005-03-24
US60/664,932 2005-03-24
US69901905P 2005-07-14 2005-07-14
US60/699,019 2005-07-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007522769A Division JP5435865B2 (ja) 2004-07-22 2005-07-21 疾患処置におけるｍｇｄ−ｃｓｆのための組成物およびその使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015029580A Division JP2015133970A (ja) 2004-07-22 2015-02-18 疾患処置におけるｍｇｄ−ｃｓｆのための組成物およびその使用方法

Publications (3)

Publication Number Publication Date
JP2014034577A JP2014034577A (ja) 2014-02-24
JP2014034577A5 true JP2014034577A5 (enExample) 2015-04-09
JP5815638B2 JP5815638B2 (ja) 2015-11-17

Family

ID=35448388

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2007522769A Expired - Fee Related JP5435865B2 (ja) 2004-07-22 2005-07-21 疾患処置におけるｍｇｄ−ｃｓｆのための組成物およびその使用方法
JP2013226693A Expired - Fee Related JP5815638B2 (ja) 2004-07-22 2013-10-31 疾患処置におけるｍｇｄ−ｃｓｆのための組成物およびその使用方法
JP2015029580A Pending JP2015133970A (ja) 2004-07-22 2015-02-18 疾患処置におけるｍｇｄ−ｃｓｆのための組成物およびその使用方法
JP2016103092A Pending JP2016146850A (ja) 2004-07-22 2016-05-24 疾患処置におけるｍｇｄ−ｃｓｆのための組成物およびその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007522769A Expired - Fee Related JP5435865B2 (ja) 2004-07-22 2005-07-21 疾患処置におけるｍｇｄ−ｃｓｆのための組成物およびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015029580A Pending JP2015133970A (ja) 2004-07-22 2015-02-18 疾患処置におけるｍｇｄ−ｃｓｆのための組成物およびその使用方法
JP2016103092A Pending JP2016146850A (ja) 2004-07-22 2016-05-24 疾患処置におけるｍｇｄ−ｃｓｆのための組成物およびその使用方法

Country Status (7)

Country Link
US (4) US20070264277A1 (enExample)
EP (3) EP2479277B1 (enExample)
JP (4) JP5435865B2 (enExample)
AT (1) ATE540973T1 (enExample)
AU (1) AU2005267062C1 (enExample)
CA (1) CA2574654C (enExample)
WO (1) WO2006012451A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
ATE454455T1 (de) * 2005-01-27 2010-01-15 Five Prime Therapeutics Inc Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung
WO2008073660A1 (en) * 2006-11-09 2008-06-19 University Of Washington Molecules and methods for treatment and detection of cancer
CA2719582A1 (en) * 2008-03-25 2009-10-01 Amarantus Therapeutics, Inc. Methods and compositions for treating parkinson's disease with manf
WO2009137631A2 (en) * 2008-05-07 2009-11-12 Wintherix Llc Methods for identifying compounds that affect expression of cancer-related protein isoforms
US8183207B2 (en) 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
US8080246B2 (en) 2008-11-26 2011-12-20 Five Prime Therapeutics, Inc. Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
RS58693B1 (sr) 2009-12-10 2019-06-28 Hoffmann La Roche Antitela koja poželjno vezuju ekstracelularni domen 4 humanog csf1r, i njihova primena
BR112012022046A2 (pt) 2010-03-05 2017-02-14 F Hoffamann-La Roche Ag ''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''.
CN102918060B (zh) 2010-03-05 2016-04-06 霍夫曼-拉罗奇有限公司 抗人csf-1r抗体及其用途
SG10201911345WA (en) 2010-05-04 2020-01-30 Five Prime Therapeutics Inc Antibodies that bind csf1r
US20110312506A1 (en) * 2010-06-17 2011-12-22 Dilyx Biotechnologies, LLC Methods and kits for screening protein solubility
JP6242804B2 (ja) 2011-12-15 2017-12-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
CN104684582A (zh) 2012-08-31 2015-06-03 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
US20150329639A1 (en) * 2012-12-12 2015-11-19 University Of Virginia Patent Foundation Compositions and methods for regulating erythropoiesis
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
JP6534380B2 (ja) 2014-02-25 2019-06-26 コーニング インコーポレイテッド スフェロイド作製用デバイス、スフェロイドの回収方法及び製造方法
US11175268B2 (en) 2014-06-09 2021-11-16 Biometry Inc. Mini point of care gas chromatographic test strip and method to measure analytes
JP6903574B2 (ja) 2014-06-09 2021-07-14 バイオメトリー・インコーポレイテッドＢｉｏｍｅｔｒｙ Ｉｎｃ． 検体を測定するための低コストテストストリップ及び方法
CA2951156A1 (en) 2014-06-23 2015-12-30 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US20160060597A1 (en) * 2014-08-28 2016-03-03 The University Of Maryland, Baltimore Functional myelination of neurons
PL3212670T3 (pl) 2014-10-29 2021-06-14 Five Prime Therapeutics, Inc. Leczenie skojarzone nowotworów
JP2017535794A (ja) * 2014-11-03 2017-11-30 バイオインセプト、エルエルシー 免疫調節不全についてのマーカーとしてのｐｉｆ結合
EA201791421A1 (ru) 2014-12-22 2017-10-31 Файв Прайм Терапьютикс, Инк. Антитела против csf1r для лечения pvns
CA2980460A1 (en) 2015-04-13 2016-10-20 Five Prime Therapeutics, Inc. Combination therapy for cancer
ES2988367T3 (es) 2016-07-19 2024-11-20 Biometry Inc Métodos y sistemas para medir analitos utilizando tiras de prueba calibrables por lotes
EP3504239B1 (en) 2016-08-25 2024-05-29 F. Hoffmann-La Roche AG Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
EP3558360A1 (en) 2016-12-22 2019-10-30 F. Hoffmann-La Roche AG Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
WO2018133937A1 (en) * 2017-01-19 2018-07-26 Biontech Ag Engineered cells for inducing tolerance
CN107130009A (zh) * 2017-07-13 2017-09-05 华南理工大学 一种具有免疫活性和抗红细胞溶血活性的新型多肽及其制备方法
CA3073531A1 (en) 2017-09-13 2019-03-21 Five Prime Therapeutics, Inc. Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
CN109456989B (zh) * 2018-10-31 2022-03-29 陕西慧康生物科技有限责任公司 一种提高毕赤酵母分泌表达的载体的构建方法
CN109593126B (zh) * 2018-11-28 2019-11-22 山西锦波生物医药股份有限公司 多肽、其生产方法和用途
CN109468361B (zh) * 2018-11-29 2021-11-02 电子科技大学 鱼类自然杀伤细胞杀伤细菌感染的单核/巨噬细胞能力的测定方法
CN109596839A (zh) * 2018-12-25 2019-04-09 广州万孚生物技术股份有限公司 人和肽素快速定量检测方法与试剂盒
WO2020148338A1 (en) * 2019-01-15 2020-07-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy
CN111150841B (zh) * 2019-12-31 2023-08-15 优锐生物医药科技(深圳)有限公司 一种主动免疫调控微粒及其制备方法和应用
CN114113602B (zh) * 2020-08-28 2024-07-02 香港城市大学深圳研究院 免疫球蛋白相关凝血因子x作为急性心肌梗死的生物标志物
US20240335562A1 (en) * 2021-08-04 2024-10-10 Alpine Biotherapeutics Corporation Sustainable ocular cell-mediated intraocular delivery of cellular therapeutics for treatment of ocular diseases or disorders

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4433092A (en) 1981-03-09 1984-02-21 Champion Spark Plug Company Green ceramic of lead-free glass, conductive carbon, silicone resin and AlPO4, useful, after firing, as an electrical resistor
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
JPH07119760B2 (ja) 1984-07-24 1995-12-20 コモンウエルス・セ−ラム・ラボラトリ−ズ・コミッション ミモトープを検出または決定する方法
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
EP0232262A4 (en) 1985-08-15 1989-09-19 Stauffer Chemical Co TRYPTOPHANE GENERATING MICROORGANISM.
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5831036A (en) * 1987-05-04 1998-11-03 Dana Farber Cancer Institute Soluble fragments of human intercellular adhesion molecule-1
JP3015383B2 (ja) 1987-09-11 2000-03-06 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 形質導入した線維芽およびそれらの使用
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
EP0484416A1 (en) * 1989-07-27 1992-05-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Regulation of nerve growth factor synthesis in the central nervous system
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
DK0464533T3 (da) 1990-06-28 1999-04-26 Gen Hospital Corp Fusionsproteiner med immunglobulindele, deres fremstilling og anvendelse
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ATE240740T1 (de) 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5399349A (en) 1992-02-06 1995-03-21 Paunescu; Calin Treatment of acne
US5480971A (en) 1993-06-17 1996-01-02 Houghten Pharmaceuticals, Inc. Peralkylated oligopeptide mixtures
EP0723556A4 (en) 1993-10-14 2003-03-19 Immunex Corp FAS ANTAGONISTS AND THEIR APPLICATIONS
US5643786A (en) * 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
US6395964B1 (en) 1995-10-24 2002-05-28 The Texas A&M University System Oral immunization with transgenic plants
EP1469883A2 (en) 1998-02-19 2004-10-27 Xcyte Therapies, Inc. Compositions and methods for regulating lymphocyte activation
US20040001826A1 (en) * 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20040048249A1 (en) * 2000-01-21 2004-03-11 Tang Y. Tom Novel nucleic acids and secreted polypeptides
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2002232596A1 (en) * 2000-12-13 2002-06-24 Incyte Genomics, Inc. Secreted human proteins
WO2002068579A2 (en) * 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
AU2003303305A1 (en) * 2002-10-02 2004-09-30 Nuvelo,Inc. Novel nucleic acids and polypeptides

Similar Documents

Publication Publication Date Title
JP2014034577A5 (enExample)
Rochman et al. The role of thymic stromal lymphopoietin in CD8+ T cell homeostasis
Jordan et al. Human interferon lambda-1 (IFN-λ1/IL-29) modulates the Th1/Th2 response
Tang et al. The therapeutic effect of ICAM-1-overexpressing mesenchymal stem cells on acute graft-versus-host disease
Nagasaka et al. Osteopontin is produced by mast cells and affects IgE‐mediated degranulation and migration of mast cells
Castro-Manrreza et al. Human mesenchymal stromal cells from adult and neonatal sources: a comparative in vitro analysis of their immunosuppressive properties against T cells
Jones et al. Loss of CD4+ T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells
CN106659742B (zh) 表达免疫应答刺激细胞因子以吸引和/或激活免疫细胞的基因修饰间充质干细胞
Gao et al. Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma
Joo et al. Serum from patients with SLE instructs monocytes to promote IgG and IgA plasmablast differentiation
Martini et al. Aging induces cardiac mesenchymal stromal cell senescence and promotes endothelial cell fate of the CD90+ subset
Zhou et al. Human umbilical cord-derived mesenchymal stem cells improve learning and memory function in hypoxic-ischemic brain-damaged rats via an IL-8-mediated secretion mechanism rather than differentiation pattern induction
Nakamura et al. Bronchial epithelial cells regulate fibroblast proliferation
Fang et al. Skeletal muscle stem cells confer maturing macrophages anti-inflammatory properties through insulin-like growth factor-2
CN108779158A (zh) 热稳定性fgf2多肽、其用途
US20240122979A1 (en) Chimeric Cytokine Receptors
Zhao et al. MAPK phosphatase-1 deficiency exacerbates the severity of imiquimod-induced psoriasiform skin disease
KR101636139B1 (ko) 면역조절능이 우수한 sRAGE 과발현 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
Zhang et al. The immunologic properties of undifferentiated and osteogenic differentiated mouse mesenchymal stem cells and its potential application in bone regeneration
Hajam et al. The expanding impact of T-regs in the skin
Shawki et al. Immunomodulatory effects of umbilical cord‐derived mesenchymal stem cells
Ma et al. Modulation of liver regeneration via myeloid PTEN deficiency
Lai et al. A tetrameric form of CD40 ligand with potent biological activities in both mouse and human primary B cells
Malon et al. Involvement of calcitonin gene-related peptide and CCL2 production in CD40-mediated behavioral hypersensitivity in a model of neuropathic pain
Jiang et al. Adipose tissue-derived stem cells modulate immune function in vivo and promote long-term hematopoiesis in vitro using the aGVHD model